AlzeCure Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Selling, General & Admin	11.88	11.47	10.6	10.17	11.27	Upgrade
Research & Development	37.49	24.98	27.71	46.18	66.72	Upgrade
Other Operating Expenses	-1.66	-0.28	0.04	0.22	0.16	Upgrade
Operating Expenses	47.71	36.18	38.34	56.57	78.14	Upgrade
Operating Income	-47.71	-36.18	-38.34	-56.57	-78.14	Upgrade
Interest Expense	-0.27	-0.02	-0.01	-0	-0	Upgrade
Interest & Investment Income	0.49	0.93	1.1	0.21	0.15	Upgrade
Currency Exchange Gain (Loss)	-0.18	0.03	0.08	0.13	0.22	Upgrade
Pretax Income	-47.67	-35.23	-37.17	-56.24	-77.78	Upgrade
Income Tax Expense	-0.02	-	-	-	-	Upgrade
Net Income	-47.65	-35.23	-37.17	-56.24	-77.78	Upgrade
Net Income to Common	-47.65	-35.23	-37.17	-56.24	-77.78	Upgrade
Shares Outstanding (Basic)	100	77	62	48	38	Upgrade
Shares Outstanding (Diluted)	100	77	62	48	38	Upgrade
Shares Change (YoY)	30.26%	24.26%	30.17%	26.30%	-	Upgrade
EPS (Basic)	-0.47	-0.46	-0.60	-1.18	-2.06	Upgrade
EPS (Diluted)	-0.47	-0.46	-0.60	-1.18	-2.06	Upgrade
Free Cash Flow	-34.59	-35.25	3.06	-99.91	-70.69	Upgrade
Free Cash Flow Per Share	-0.34	-0.46	0.05	-2.10	-1.87	Upgrade
EBITDA	-46.45	-35.88	-37.87	-56	-77.57	Upgrade
D&A For EBITDA	1.27	0.29	0.48	0.57	0.58	Upgrade
EBIT	-47.71	-36.18	-38.34	-56.57	-78.14	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.